QT VASCULAR LTD.

(Company Registration No. 201305911K)

(Incorporated in Singapore)

PROPOSED RESTRUCTURING OF QT VASULAR LTD. BY WAY OF A SCHEME OF ARRANGEMENT UNDER SECTION 210 OF THE COMPANIES ACT 1967 FOR THE PROPOSED TRANSFER OF LISTING STATUS OF QT VASCULAR LTD. TO NEWCO

- RESPONSE FROM THE SGX-REGCO IN RELATION TO ENQUIRY ON APPLICATION OF CHAPTER 4 AND RULES 1307, 1308 AND 1309 OF THE CATALIST RULES IN RELATION TO THE PROPOSED RESTRUCTURING BY WAY OF THE SCHEME

The board of directors ("Directors" or "Board") of QT Vascular Ltd. ("Company", and together with its subsidiaries, "Group") refers to the announcements made by the Company on 25 May 2021, 18 November 2021, 19 November 2021, 30 November 2021, 2 December 2021, 16 December 2021, 22 December 2021, 24 December 2021, 30 December 2021, 8 January 2022, 13 January 2022, 14 January 2022 and 2 March 2022, and the circular dated 24 December 2021. Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the announcement by the Company dated 2 March 2022 in relation to the Proposed Restructuring by way of the Scheme ("Scheme Announcement").

Further to the Scheme Announcement, the Directors wish to announce that the Company has on 22 March 2022 received a response from the Singapore Exchange Regulation Pte Ltd ("SGX-Regco") that the guidance (including the conditions stated therein) issued by the SGX-Regco on 16 November 2021 ("SGX-Regco Guidance") and announced by the Company on 18 November 2021 remain applicable to the Scheme.

According to the SGX-Regco Guidance, the listing and delisting requirements under Chapter 4 and Rules 1307, 1308 and 1309 of the Catalist Rules are not applicable to the Scheme, subject to the following conditions being met:

(a) the Company's compliance with the SGX-ST's listing requirements;

(b) announcement of the implementation of the Scheme and the fulfilment of the conditions precedent;

(c) approval being obtained from Shareholders and the relevant authorities for the Scheme;

(d) sanction of the Scheme by the High Court of Singapore;

(e) submission of an undertaking (in the form set out in Appendix 7H of the Catalist Rules) from each of the directors and executive officers of NewCo to comply with the Catalist Rules; and

(f) submission of an undertaking from the Company that any subsequent disposal of the Company's current business is subject to shareholders' approval.

Shareholders should note that the response from the SGX-Regco is not to be taken as an indication of the merits of the Scheme, NewCo Shares, NewCo, the Company and/or its subsidiaries. The SGX-Regco also reserves the right to amend and/or vary its response, which is subject to changes in the SGX-Regco's policies.

SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY AS THERE IS NO CERTAINTY OR ASSURANCE THAT THE SCHEME WILL BE COMPLETED. SHAREHOLDERS AND OTHER INVESTORS ARE ADVISED TO READ ANY ANNOUNCEMENTS BY THE COMPANY CAREFULLY. THEY SHOULD CONSULT THEIR STOCKBROKERS, BANK MANAGERS, SOLICITORS, ACCOUNTANTS, TAX ADVISORS OR OTHER PROFESSIONAL ADVISORS IF THEY ARE IN ANY DOUBT AS TO THE ACTIONS THEY SHOULD TAKE.

By Order of the Board of Directors
QT VASCULAR LTD.

Thomas Tan Gim Chua
Chief Executive Officer
22 March 2022

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.